• slide

    Current practice insights into the use of biologicals

  • slide

    Rapid access to our in-house patient-centric Database Network

  • slide

    An experienced sparring partner for your European healthcare questions

  • slide

    Dedicated to research real-life health care for the benefit of patients

  • News


    #ABOARDproject is begonnen! Een bijzondere en nationale samenwerking waarbij meer dan 30 partners, waaronder STIZON, Stichting Informatievoorziening voor Zorg en Onderzoek en wijzelf, PHARMO Institute for Drug Outcomes Research, onze krachten bun...

    New Data Ambulatory Consultations

    NEW DATA available in the PHARMO Database Network – Ambulatory Consultations This new dataset comprises all ambulatory consultations (i.e. out-patient records). This is a great asset for PHARMO, as all specialist visits and out-patient procedure...

    Algoritme coronavirus risico

    Onderzoekers van Amsterdam UMC hebben een algoritme ontwikkeld dat voor patiënten van elke huisartspraktijk het risico berekent om ernstig ziek te worden door het coronavirus.

  • Events

    Annual Conference International Society for Pharmacoepidemiology

    Annual Conference International Society for Pharmacoepidemiology ICPE All AccessVirtual Event ( September 16-17, 2020) We are pleased to announce that PHARMO will present their study ‘Infliximab Use in the Netherlands: Uptake And Characteristic...

  • Vacancy

    (Senior) Research Account Manager

    Wil je bijdragen aan meer transparantie in de gezondheidszorg? Heb je ervaring als onderzoeker en heb je affiniteit met het vertalen van de vragen en onderzoek behoeften van de klant naar een onderzoeksvoorstel/-project?Heb je internationale commerc...

  • icon

    What we do

    As an independent research organisation dedicated to the study of epidemiology, drug utilisation, drug safety, health outcomes, and utilisation of healthcare resources PHARMO assists its clients in their decision-making.

  • icon

    What we have

    PHARMO Database Network: we have rapid access to our rich population-based network of databases. Data are derived from different primary and secondary healthcare settings. For our observational studies disease-specific cohorts are created from the various databases.


  • Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands

    Read more
  • No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study

    Read more
  • Trends in mortality, cardiovascular complications, and risk factors in type 2 diabetes

    Read more
  • The risk of developing cardiovascular disease is increased for prostate cancer patients who are pharmaceutically treated for depression

    Read more